Core Insights - Viatris has launched Inpefa (sotagliflozin) in the UAE, marking the first commercialization of this treatment in its territories, with plans for future launches in multiple countries to expand access outside the U.S. and Europe [1][3] Product Overview - Inpefa is the first and only dual SGLT1/2 inhibitor approved for heart failure treatment, aimed at reducing cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors [2][6] - The approval of Inpefa is based on two pivotal Phase 3 trials, SOLOIST-WHF and SCORED, which enrolled over 11,800 patients globally, demonstrating significant reductions in major cardiovascular events [3][5] Clinical Efficacy - In the SOLOIST-WHF trial, Inpefa reduced the composite risk of heart failure hospitalization, urgent visits, and cardiovascular death by 33% compared to placebo, with benefits increasing to 51% when initiated prior to discharge [3] - In the SCORED trial, Inpefa achieved a 25% reduction in the same composite endpoint among patients with type 2 diabetes and chronic kidney disease [3] - The treatment also showed a 23% reduction in major adverse cardiovascular events (MACE), with significant reductions in myocardial infarction (32%) and stroke (34%) [3] Market Context - Heart failure is the leading cause of hospitalization globally, affecting over 64 million people, with substantial post-discharge mortality and readmission rates [4] - The 30-day post-discharge mortality rate is approximately 6.7%, with readmission rates averaging 13%, increasing to 23% mortality and 36% readmission at one year post-discharge [4] Company Strategy - Viatris aims to expand its innovative portfolio in cardiovascular diseases, leveraging its scientific leadership and commercial legacy [3][9] - The company has submitted regulatory filings for Inpefa in several countries, including Canada, Australia, and Mexico, and plans to broaden global submissions in the coming years [3][9]